Iridium-monodentate phosphoramidite-catalyzed asymmetric hydrogenation of substituted benzophenone N-H imines

Journal of the American Chemical Society

Volumn 132, Issue 7, 2010, Pages 2124-2125

  Hou, Guohua ^a   Tao, Ran ^b,c   Sun, Yongui ^b   Zhang, Xumu ^a   Gosselin, Francis ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASYMMETRIC HYDROGENATION; CHIRAL AMINES; MONODENTATES; PHOSPHORAMIDITES;

ENANTIOSELECTIVITY; IRIDIUM; NITROGEN COMPOUNDS;

HYDROGENATION;

BENZOPHENONE; HYDROGEN; IMINE; IRIDIUM; MONODENTATE PHOSPHORAMIDITE; NITROGEN; PHOSPHORAMIDOUS ACID DERIVATIVE; UNCLASSIFIED DRUG; AMINE; BENZOPHENONE DERIVATIVE; LIGAND; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND; PHOSPHORAMIDOUS ACID;

ARTICLE; ASYMMETRIC CATALYSIS; CATALYSIS; CATALYST; CHEMICAL BOND; CHIRALITY; ENANTIOSELECTIVITY; HYDROGENATION; STEREOSPECIFICITY; SUBSTITUTION REACTION; CHEMISTRY; STEREOISOMERISM; SYNTHESIS;

AMINES; BENZOPHENONES; CATALYSIS; HYDROGENATION; IMINES; IRIDIUM; LIGANDS; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; STEREOISOMERISM;

EID: 77950788901     PISSN: 00027863     EISSN: 15205126     Source Type: Journal    
DOI: 10.1021/ja909583s     Document Type: Article

References (45)

1. (a) Bishop, M. J.; McNutt, R. W. Bioorg. Med. Chem. Lett. 1995, 5, 1311.
2. (b) Spencer, C. M.; Foulds, D.; Peters, D. H. Drugs 1993, 46, 1055.
3. (c) Sakurai, S.; Ogawa, N.; Suzuki, T.; Kato, K.; Ohashi, T.; Yasuda, S.; Kato, H.; Ito, Y. Chem. Pharm. Bull. 1996, 44, 765. Patent applications include:
4. (d) Tulshian, D.; Ho, G. D.; Silverman, L.; Matasi, J. J.; McLeod, R. L.; Hey, J. A.; Chapman, R. W.; Bercovici, A.; Cuss, F. M. WO 01/ 07050 A1 (Schering-Plough).
5. (e) Jolidon, S.; Narquizian, R.; Pinard, E. WO 2008/022938 A1 (Hoffman-LaRoche).
6. (f) Ducray, P.; Cavaliero, T.; Lorhmann, M.; Bouvier, J. WO 2008/062006 A1 (Novartis).
7. (g) Baker, R. K; Hale, J. J.; Maio, S.; Rupprecht, K. M. WO 2007/062193 A1 (Merck). Cetirizine·HCl, a histamine H1-receptor inverse agonist is commercialized as Zyrtec/Reactine by Pfizer.
8. (a) Tomioka, K.; Inoue, I.; Shindo, M.; Koga, K. Tetrahedron Lett. 1990, 31, 6681.
9. (b) Pridgen, L. N.; Mokhallalati, M. K.; Wu, M. J. J. Org. Chem. 1992, 57, 1237.
10. (c) Delorme, D.; Berthelette, C.; Lavoie, R.; Roberts, E. Tetrahedron: Asymmetry 1998, 9, 3963.
11. (d) Plobeck, N.; Powell, D. Tetrahedron: Asymmetry 2002, 13, 303.
12. (e) Pflum, D. A.; Krishnamurthy, D.; Han, Z.; Wald, S. A.; Senanayake, C. H. Tetrahedron Lett. 2002, 43, 923.
13. (f) Cabello, N.; Kizirian, J.-C.; Alexakis, Tetrahedron Lett. 2004, 45, 4639.
14. (g) Weix, D. J.; Shi, Y.; Ellman, J. A. J. Am. Chem. Soc. 2005, 127, 1092.
15. (h) Bolshan, Y.; Batey, R. A. Org. Lett. 2005, 7, 1481.
16. Rh-catalyzed enantioselective additions of arylstannanes: (a) Hayashi, T.; Ishigedani, M. J. Am. Chem. Soc. 2000, 122, 976. Aryltitaniums:
17. (b) Hayashi, T.; Kawai, M.; Tokunaga, N. Angew. Chem. Int. Ed. 2004, 43, 6125. Arylboronic acids:
18. (c) Kuriyama, M.; Soeta, T.; Hao, X.; Chen, Q.; Tomioka, K. J. Am. Chem. Soc. 2004, 126, 8128.
19. (d) Duan, H.-F.; Jia, Y.-X.; Wang, L.-X.; Zhou, Q.-L. Org. Lett. 2006, 8, 2567.
20. (e) Jagt, R. B. C.; Toullec, P. Y.; Geerdink, D.; de Vries, J. G.; Feringa, B. L.; Minnaard, A. J. Angew. Chem. Int. Ed. 2006, 45, 2789.
21. (f) Wang, Z.-Q.; Feng, C.-G.; Xu, M.-H.; Lin, G.-Q. J. Am. Chem. Soc. 2007, 129, 5336. Also see ref 2g.
22. 2Zn to N-formyl imines has also been reported. See: Hermanns, N.; Dahmen, S.; Bolm, C.; Bräse, S. Angew. Chem. Int. Ed 2002, 41, 3692.
23. Clayden, J.; Dufour, J.; Grainger, D. M.; Helliwell, M. J. Am. Chem. Soc. 2007, 129, 7488.
24. 3 complex followed by nucleophilic displacement, see: Corey, E. J.; Helal, C. J. Tetrahedron Lett. 1996, 37, 4837.
25. (a) Ohkuma, T.; Koizumi, M.; Ikehira, H.; Yokozawa, T.; Noyori, R. Org. Lett. 2000, 2, 659.
26. (b) Chen, C.-y.; Reamer, R. A.; Chilenski, J. R.; McWilliams, C. J. Org. Lett. 2003, 5, 5039.
27. (c) Yamano, T.; Oi, S.; Yamashita, M. Patent WO 01/040162 A1, 2001 (Takeda Chemical Industries).
28. (a) Hantzsch, A.; Kraft, F. Ber. Dtsch. Chem. Ges. 1891, 24, 3511.
29. (b) Moureu, C.; Mignonac, G. Compt. Rend. 1913, 156, 1801.
30. (c) Pickard, P. L.; Vaughan, D. J. J. Am. Chem. Soc. 1950, 72, 5017.
31. (d) Pickard, P. L.; Tolbert, T. L. Org. Synth. 1964, 44, 51.
32. For reviews, see: (a) Tang, W.; Zhang, X. Chem. Rev. 2003, 103, 3029.
33. (b) Kobayashi, S.; Ishitani, H. Chem. Rev. 1999, 99, 1069.
34. (c) Handbook of Homogeneous Hydrogenation; de Vries, J. G., Elsevier, C. J., Eds.; Wiley-VCH: Weinheim, Germany, 2007.
35. Hou, G.; Gosselin, F.; Li, W.; McWilliams, C. J.; Sun, Y.; O'Shea, P. D.; Davies, I. W.; Chen, C.-y.; Zhang, X. J. Am. Chem. Soc. 2009, 131, 9882.
36. For a Pd-catalyzed C-H activation approach, see: (a) Zhou, C.; Larock, R. C. J. Am. Chem. Soc. 2004, 126, 2302.
37. (b) Zhou, C.; Larock, R. C. J. Org. Chem. 2006, 71, 3551.
38. 2 to benzophenones, see: Kruger, C.; Rochow, E.; Wanagat, U. Chem. Ber. 1963, 96, 2132.
39. ForRh-catalyzed asymmetric hydrogenation of protected β-dehydroamino esters using ligand 4, see: Peña, D.; Minnaard, A. J.; de Vries, J. G.; Feringa, B. L. J. Am. Chem. Soc. 2002, 124, 14552.
40. (a) Minnaard, A. J.; Feringa, B. L.; Lefort, L.; de Vries, J. G. Acc. Chem. Res. 2007, 40, 1267.
41. (b) Lefort, L.; Boogers, J. A. F.; Minnaard, A. J.; Feringa, B. L.; de Vries, J. G. Org. Lett. 2004, 6, 1733.
42. Mršić, N.; Minnaard, A. J.; Feringa, B. L.; de Vries, J. G. J. Am. Chem. Soc. 2009, 131, 8358.
43. Inferior results were obtained with, metal/ligand ratios of 1:1 (76% conv, 56% ee) and 1:3 (11% conv, 41% ee) using imine la. Single monodentate phosphoramidite-iridium complexes can afford high enantioselectivities; see: Giacomina, F.; Meetsma, A.; Panella, L.; Lefort, L.; de Vries, A. H. M.; de Vries, J. G. Angew. Chem. Int. Ed. 2007, 46, 1497.
44. Chloride additives improve the enantioselectivity in Ir-phosphoramidite- catalyzed hydrogenations of quinolines. See: Mršić, N.; Lefort, L.; Boogers, J. A. F.; Minnaard, A. J.; Feringa, B. L.; de Vries, J. G. Adv. Synth. Catal. 2008, 350, 1081.
45. Seebach, D. Angew. Chem. Int Ed. 1990, 29, 1320.